Friday, January 9, 2026

Supernova Remnant Video From NASA’s Chandra Is Decades in Making - UNIVERSE

 

A new video shows changes in Kepler’s Supernova Remnant using data from NASA’s Chandra X-ray Observatory captured over more than two and a half decades with observations taken in 2000, 2004, 2006, 2014, and 2025. In this video, which is the longest-spanning one ever released by Chandra, X-rays (blue) from the telescope have been combined with an optical image (red, green, and blue) from Pan-STARRS.

X-ray: NASA/CXC/SAO; Optical: Pan-STARRS

A new video shows the evolution of Kepler’s Supernova Remnant using data from NASA’s Chandra X-ray Observatory captured over more than two and a half decades.

Kepler’s Supernova Remnant, named after the German astronomer Johannes Kepler, was first spotted in the night sky in 1604. Today, astronomers know that a white dwarf star exploded when it exceeded a critical mass, after pulling material from a companion star, or merging with another white dwarf. This kind of supernova is known as a Type Ia, and scientists use it to measure the expansion of the universe.

Supernova remnants, the debris fields left behind after a stellar explosion, often glow strongly in X-ray light because the material has been heated to millions of degrees from the blast. The remnant is located in our galaxy, about 17,000 light-years from Earth, allowing Chandra to make detailed  images of the debris and how it changes with time. This latest video includes its X-ray data from 2000, 2004, 2006, 2014, and 2025. This makes it the longest-spanning video that Chandra has ever released, enabled by Chandra’s longevity.

“The plot of Kepler’s story is just now beginning to unfold,” said Jessye Gassel, a graduate student at George Mason University in Virginia, who led the work. “It’s remarkable that we can watch as these remains from this shattered star crash into material already thrown out into space.” Gassel presented the new Chandra video and the associated research at the 247th meeting of the American Astronomical Society in Phoenix.

The researchers used the video to show that the fastest parts of the remnant are traveling at about 13.8 million miles per hour (2% of the speed of light), moving toward the bottom of the image. Meanwhile, the slowest parts are traveling toward the top at about 4 million miles per hour (0.5% of the speed of light). This large difference in speed is because the gas that the remnant is plowing into toward the top of the image is denser than the gas toward the bottom. This gives scientists information about the environments into which this star exploded.

“Supernova explosions and the elements they hurl into space are the lifeblood of new stars and planets,” said Brian Williams of NASA’s Goddard Space Flight Center in Greenbelt, Maryland, and principal investigator of the new Chandra observations of Kepler. “Understanding exactly how they behave is crucial to knowing our cosmic history.”

The team also examined the widths of the rims forming the blast wave of the explosion. The blast wave is the leading edge of the explosion and the first to encounter material outside of the star. By measuring how wide it is and how fast it is traveling, astronomers glean more information about both the explosion of the star and its surroundings.

NASA’s Marshall Space Flight Center in Huntsville, Alabama, manages the Chandra program. The Smithsonian Astrophysical Observatory’s Chandra X-ray Center controls science operations from Cambridge, Massachusetts, and flight operations from Burlington, Massachusetts.

To learn more about Chandra, visit: https://science.nasa.gov/chandra

Read more from NASA’s Chandra X-ray Observatory

Learn more about the Chandra X-ray Observatory and its mission here:

https://www.nasa.gov/chandra

https://chandra.si.edu

Visual Description

This release features a ten second silent video of Kepler’s expanding Supernova Remnant, located in our own galaxy, about 17,000 light-years from Earth. The video was created using X-ray data gathered in 2000, 2004, 2006, 2014, and 2025. Those distinct datasets were turned into highly-detailed visuals, creating a 25-year timelapse-style video of the growing remnant.

Kepler’s Supernova Remnant was once a white dwarf star that exploded when it exceeded its critical mass. Here, in X-ray light, the remnant resembles a cloudy neon blue ring with a diagonal cross line stretching from our upper right down to our lower left. The ring appears thinner and wispier at the bottom, with a band of white arching across the top.

As the video plays, cycling through the 5 datasets, the ring subtly, but clearly, expands, like a slowly inflating balloon. In the video, this sequence is replayed several times with dates included at our lower right, to give sighted learners time to absorb the visual information. Upon close inspection, researchers have determined that the bottom of the remnant is expanding fastest; about 13.8 million miles per hour, or 2% of the speed of light. The top of the ring appears to be expanding the slowest; about 4 million miles per hour, or 0.5% of the speed of light. The large difference in speed is because the gas that the remnant is plowing into towards the top of the image is denser than the gas towards the bottom.

Collecting and interpreting this data over decades has provided information about the environment into which the white dwarf star exploded, and has helped scientists understand how remnants change with time. 

Source: Supernova Remnant Video From NASA's Chandra Is Decades in Making - NASA  

Diabetes drugs may be changing cancer in surprising ways


Researchers are taking a closer look at how medications used to treat diabetes may also influence cancer. While diabetes itself has long been associated with higher cancer risk, scientists are now investigating whether diabetes drugs play a direct role beyond controlling blood sugar levels and body weight. A recent review examines how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may affect cancer growth by changing how cells multiply, how the immune system responds, and how inflammation develops. These insights point to possible new treatment strategies while also highlighting how much remains unknown.

Type 2 Diabetes (T2DM) has been linked to a higher likelihood of developing several types of cancer, including liver, colorectal, and breast cancer. Managing blood glucose and body weight remains essential for people with diabetes, but growing evidence suggests these factors alone do not fully explain the increased cancer risk. This has led scientists to explore how diabetes medications themselves might influence cancer, either by reducing risk or, in some cases, creating unintended effects. Understanding this connection could help clarify how diabetes treatments fit into cancer prevention and care, though further research is still needed to unravel the underlying biology.

A Closer Look at Diabetes Drugs and Cancer Biology


Published on December 10, 2025, in Precision Clinical Medicine, this review brings together current research on how anti-diabetic medications interact with cancer. The study was led by researchers at Peking University People’s Hospital and moves beyond the traditional focus on blood sugar control and weight management. Instead, it examines how drugs such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may influence cancer progression through multiple biological pathways. The findings add depth to the ongoing discussion about how diabetes treatments can affect cancer outcomes in complex and sometimes unexpected ways.


What the Evidence Shows About Specific Medications


The review analyzes both laboratory and clinical studies that explore links between diabetes medications and cancer. Metformin, one of the most commonly prescribed diabetes drugs, appears to affect cancer through several mechanisms. These include strengthening anti-cancer immune responses and slowing tumor growth by altering the tumor microenvironment (TME). Metformin also influences major cellular pathways such as AMPK, mTOR, and PI3K/AKT, which help regulate cell growth, cell death, and the formation of new blood vessels.

Other diabetes medications show potential effects as well. SGLT2 inhibitors and GLP-1 receptor agonists have been associated with changes in cancer cell growth, reduced inflammation, and increased apoptosis. However, their impact is not consistent across all cancers or drugs. For instance, metformin has shown encouraging results in lowering the risk of colorectal and liver cancers, while its role in breast cancer remains unclear. The review emphasizes that each medication works differently and that more clinical trials are needed to confirm these findings and better understand their role in cancer treatment.

Expert Perspective on Unanswered Questions


Dr. Linong Ji, a leading researcher in this area, notes that important questions remain. “While anti-diabetic medications are crucial in managing diabetes, their broader effects on cancer are still not fully understood. This review sheds light on the intricate mechanisms through which these drugs may influence cancer progression. However, the evidence is mixed, and we must continue to investigate the long-term impacts of these medications in cancer patients, as well as the potential for developing targeted therapies based on these findings.”

Toward More Personalized Treatment Strategies


The review highlights the growing importance of personalized medicine for patients who have both diabetes and cancer. A clearer understanding of how specific diabetes drugs affect cancer could help doctors tailor treatments more effectively, improving prevention strategies and patient outcomes. The findings also support the need for future clinical trials to test how existing diabetes medications might be refined for cancer therapy or used alongside standard treatments. Insights into drugs such as metformin may also guide public health efforts, especially for populations facing higher risks of both diabetes and cancer.

Paper: https://academic.oup.com/pcm/article/8/4/pbaf028/8316832

Source: https://www.sciencedaily.com/releases/2025/12/251226045322.htm 

Source: Diabetes drugs may be changing cancer in surprising ways – Scents of Science